Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4553 - Clinical significance of the expression of membrane receptors of the alternative nuclear factor-kappaB pathway in non-small cell lung cancer.


11 Sep 2017


Poster display session


Fotinos-Ioannis Dimitrakopoulos


Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390


F. Dimitrakopoulos1, V. Tzelepi2, A. Kottorou3, A. Antonacopoulou3, A. Koutras3, T. Makatsoris3, H. Kalofonos3

Author affiliations

  • 1 Oncology, University Hospital of Patras, 26504 - Rion/GR
  • 2 Department Of Histopathology, University of Patras, Patras/GR
  • 3 Division Of Oncology, Department Of Medicine, University of Patras, Patras/GR


Abstract 4553


During the last decade, the alternative pathway of Nuclear Factor-kappaB (NF-κB) has gained importance due to its implication in cancer initiation and development where it has been shown to be deregulated. It is mainly activated thgough the membrane receptors Lymphotoxin β Receptor (LTβR), CD40, B-cell activating factor receptor (BAFFR) and Receptor Activator of NF-κB (RANK), having an important role in immune response and multiple cancer cell functions.


Immunohistochemical analysis of the expression of these 4 receptors was performed on 130 tumour and adjacent non neoplastic formalin fixed and paraffin embedded tissue samples from patients with non-small cell lung cancer (NSCLC).


CD40 and BAFFR expression was higher in neoplastic compared to adjacent non-neoplastic tissue (P = 0.006 and 0.001, respectively) while no such differences were observed for RANK and LTβR. Moreover, CD40 levels in tumour infiltrating lymphocytes (TILs) correlated with development of metastases in adrenals (P = 0.003), liver (P 


Protein levels of CD40 and BAFFR are altered in NSCLC in agreement with a deregulation of the alternative NF-κB pathway previously shown by our team. CD40, BAFFR and LTβR tissue protein levels appear to constitue biomarkers for specific clinicopathologcal parameters including survival, stage and histological subtype.

Clinical trial identification

Legal entity responsible for the study

Haralabos P Kalofonos.


Hellenic Society of Medical Oncology (HeSMO).


T. Makatsoris: Travel expenses from Pfizer, Roche and Astellas. Advisory fees from Roche and Boeringer. Honoraria from Roche, Sanofi, Merck and Amgen. H. Kalofonos: Consulting/advisory role: Roche, Novartis, MSD, Genesis, Pfizer, Lilly, Leo, Amgen, Janssen, Merck, Merck-Serono.Research funding Roche Pfizer, Novartis, Amgen, Bayer, Genesis Lilly, MSD, Janssen, Merck-Serono. Travel expenses: Roche, Novartis, Enorasis, Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.